Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled, Multicenter, Study to Demonstrate the Efficacy at 16 Weeks of Secukinumab 150 and 300 mg s.c. and to Assess Safety, Tolerability and Long-term Efficacy up to 132 Weeks in Subjects With Moderate to Severe Nail Psoriasis

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Jun 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Secukinumab (Primary)
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Acronyms TRANSFIGURE
  • Sponsors Novartis; Novartis Pharmaceuticals Corporation

    • Most Recent Events

    • 25 Apr 2021 Results of a pooled analysis assessing the improvements of nail psoriasis for up to 2 years in patients with psoriasis or PsA with or without axial manifestations irrespective of the severity of the nail involvement across the three datasets of the TRANSFIGURE, pooled FUTURE 2-5 and MAXIMISE studies presented at the American Academy of Dermatology Virtual Meeting Experience 2021
    • 01 Jun 2020 2.5 year results from the randomized placebo controlled TRANSFIGURE study published in the British Journal of Dermatology
    • 09 Sep 2019 Results published in the British Journal of Dermatology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top